RT Journal Article
T1 Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
A1 Díez-Campelo, María
A1 Lorenzo, Jose I
A1 Itzykson, Raphael
A1 Rojas, Silvia M
A1 Berthon, Céline
A1 Luño, Elisa
A1 Beyne-Rauzy, Odile
A1 Perez-Oteyza, Jaime
A1 Vey, Norbert
A1 Bargay, Joan
A1 Park, Sophie
A1 Cedena, Teresa
A1 Bordessoule, Dominique
A1 Muñoz, Juan A
A1 Gyan, Emmanuel
A1 Such, Esperanza
A1 Visanica, Sorin
A1 López-Cadenas, Félix
A1 de Botton, Stéphane
A1 Hernández-Rivas, Jesús M
A1 Ame, Shanti
A1 Stamatoullas, Aspasia
A1 Delaunay, Jacques
A1 Salanoubat, Celia
A1 Isnard, Françoise
A1 Guieze, Romain
A1 Pérez Guallar, Joan
A1 Badiella, Llorenc
A1 Sanz, Guillermo
A1 Cañizo, Consuelo
A1 Fenaux, Pierre
K1 azacitidine
K1 chromosome 7 abnormalities
K1 high risk MDS
K1 time-dependent analysis
AB Treatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients with Abn 7 treated with AZA (n = 115) versus best supportive care (BSC; n = 120), assessed AZA treatment as a time-varying variable in multivariable analysis. A Cox Regression model with time-interaction terms of overall survival (OS) at different time points confirmed that, while chromosome 7 cytogenetic categories (complex karyotype [CK] versus non-CK) and International Prognostic Scoring System risk (high versus intermediate-2) retained poor prognosis over time, AZA treatment had a favourable impact on OS during the first 3 years of treatment compared to BSC (Hazard ratio [HR] 0·5 P 
YR 2018
FD 2018-04-02
LK http://hdl.handle.net/10668/12302
UL http://hdl.handle.net/10668/12302
LA en
DS RISalud
RD Apr 6, 2025